Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer

NCT00574236 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT00574236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00574236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2006
Completion date
October 31, 2009
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer